Supplemental
and 3-year OS were observed at 100% and 81.8% respectively. Estimated 1-year and 3-year DFS were observed at 58.3% and 48.6% respectively. B Validation set: estimated 1-year and 3-year OS were observed at 100% and 81.6% respectively.
Estimated 1-year and 3-year DFS were observed at 47.3% and 44.2% respectively.
Supplemental Figure 2:
Comparative topography of training set representative CRCLM resections. Column 1: x-ray film autoradiography showing ApoF mRNA hepatocyte-specific in situ hybridization labeling. Column 2: Alcian Blue (AB) staining pattern in tumor tissue. Column 3: tissue topography with H&E staining. Column 4: x-ray film auto-radiography with macrophage-preferential PLTP mRNA in situ hybridization labeling. Column 5: ki-67 immunostaining indicating viable tumor cells. Column 6: Hyper-spectral spatially aware k-means clustering mass spectrometry imaging (MSI) data. Abbreviations: H -hepatocyte; Li -liver; M -macrophage; Sselection and T -tumor. Magnification x5.
